Pfizer-BioNTech vaccine effective against mutation in new coronavirus strains, study finds
- The research indicated the vaccine was effective in neutralising virus with the so-called N501Y mutation of the spike protein
- Scientists said the results would help calm concerns that people will not be protected by vaccines being given to millions around the world
The study by Pfizer and scientists from the University of Texas Medical Branch, which has not yet been peer-reviewed, indicated the vaccine was effective in neutralising virus with the so-called N501Y mutation of the spike protein.
The mutation could be responsible for greater transmissibility and there had been concern it could also make the virus escape antibody neutralisation elicited by the vaccine, said Phil Dormitzer, one of Pfizer’s top viral vaccine scientists.
The first results of tests on the variants offer a glimmer of hope while more studies are carried out as Britain and other countries try to tame the more infectious strains which authorities believe are driving a surge in infections that could overwhelm health care systems.
UK rolls out Oxford-AstraZeneca vaccine amid fears about new strain
The Pfizer-BioNTech study was conducted on blood taken from people who had been given the vaccine. Its findings are limited because it does not look at the full set of mutations found in either of the new variants of the rapidly spreading virus.
Dormitzer said it was encouraging that the vaccine appears effective against the mutation, as well as 15 other mutations the company has previously tested against.
“So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news,” he said. “That doesn’t mean that the 17th won’t.”
Dormitzer said another mutation found in the South African variant, called the E484K mutation, was also concerning.
03:57
Coronavirus: what we know so far about the new strain of Covid-19
The researchers plan to run similar tests to establish whether the vaccine is effective against other mutations found in the British and South African variants and hope to have more data within weeks.
The variants are said by scientists to be more transmissible than previously dominant ones, but they are not thought to cause more serious illness.
Scientists said the results of the study would help calm concerns that people will not be protected by vaccines being given to millions around the world in the fight against the pandemic, which has killed more than 1.8 million people and roiled economies.
But they cautioned that more clinical tests and data are still needed to come to a definitive conclusion.
What the world can expect from Covid-19 vaccines in 2021
“This is good news, mainly because it is not bad news,” said Stephen Evans, professor of pharmacoepidemiology, London School of Hygiene & Tropical Medicine.
“So, yes this is good news, but it does not yet give us total confidence that the Pfizer (or other) vaccines will definitely give protection.”
AstraZeneca, Moderna and CureVac are also testing whether their shots work against the fast-spreading variants. They have said they expect them to be effective, but the timing of those studies are not known.
A senior British lawmaker expressed concerns in an interview on Friday that Covid-19 vaccines might not work properly against the South African variant. He was not responding to questions about Friday’s data.
09:50
SCMP Explains: What's the difference between the major Covid-19 vaccines?
The Pfizer/BioNTech vaccine and the one from Moderna, which use synthetic messenger RNA technology, can be quickly tweaked to address new mutations of a virus if necessary. Scientists have suggested the changes could be made in as little as six weeks.
The variant is not the first of the pandemic to emerge and Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh, said these types of study will be needed as they appear.
“It may be necessary to tweak the vaccine over time,” she said.
Meanwhile, Britain’s medical regulator on Friday approved Moderna’s vaccine for use, the health ministry said, adding that it had agreed to purchase an additional 10 million doses of the shot as it eyed a spring roll-out of the jab.
Three Covid-19 vaccines have now been approved for use in Britain, with Pfizer/BioNTech’s shot and one developed by Oxford University and AstraZeneca already being rolled out.
